Development of cell-based high-throughput assays for the identification of inhibitors of receptor activator of nuclear factor-kappa B signaling

Assay and Drug Development Technologies

Volumn 9, Issue 1, 2011, Pages 40-49

  Ashley, Jason W ^a   McCoy, Erin M ^a   Clements, Daniel A ^a   Shi, Zhenqi ^a   Chen, Taosheng ^b   Feng, Xu ^a  

^a University of Alabama at Birmingham   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; PROLYLVALYLGLUTAMINYLGLUTAMYLGLUTAMINYLGLYCINE; PROLYLVALYLGLUTAMINYLGLUTAMYLGLUTAMYLTHREONINE; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOPLASM; DRUG IDENTIFICATION; ENZYME ACTIVITY; FOLLOW UP; HIGH THROUGHPUT SCREENING; HUMAN; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; SIGNAL TRANSDUCTION;

BIOLOGICAL ASSAY; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MACROPHAGES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 79951691795     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2010.0307     Document Type: Article

References (42)

1. Teitelbaum SL: Bone resorption by osteoclasts. Science 2000;289:1504-1508.
2. Teitelbaum SL, Ross FP: Genetic regulation of osteoclast development and function. [Review]. Nat Rev Genet 2003;4:638-649. (Pubitemid 36917505)
3. Lian J, Stein GS: Osteoblast biology. In: Osteoporosis. Marcus R, Feldman D, Nelson DA, Rosen CJ (eds.), pp. 93-150. Elsevier Academic Press, San Diego, 2008.
4. Goldring SR: Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. [Review]. Rheumatology 2003;42 Suppl 2:ii11-ii16. (Pubitemid 37220895)
5. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. [Review]. Nat Rev Cancer 2002;2:584-593. (Pubitemid 37328925)
6. Raisz LG: Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-3325. (Pubitemid 43121814)
7. Stefanick ML: Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005;118 Suppl 12B:64-73.
8. Prince R, Muchmore DB, Siris ES: Estrogen analogues: selective estrogen receptor modulators and phytoestrogens. In: Osteoporosis. Marcus R, Feldman D, Nelson DA, Rosen CJ, (eds.), pp. 1705-1723. Academic Press, San Diego, 2008.
9. Miller P: Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Osteoporosis. Marcus R, Feldman D, Nelson DA, Rosen CJ, (eds.), pp. 1725-1742. Academic Press, San Diego, 2008.
10. Gruber HE, Ivey JL, Baylink DJ, et al.: Long-term calcitonin therapy inpostmenopausal osteoporosis. Metabolism 1984;33:295-303. (Pubitemid 14135344)
11. Miller PD, Derman RJ: What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos Int 2010 [Epub ahead of print].
12. Stepan JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P: Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. [Review]. Endocr Regul 2003;37:225-238. (Pubitemid 38175992)
13. Lufkin EG, Sarkar S, Kulkarni PM, et al.: Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. [Review]. Curr Med Res Opin 2004;20:351-357. (Pubitemid 38339175)
14. Marcus R, Wong M, Heath H, III, Stock JL: Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. [Review]. Endocr Rev 2002;23:16-37. (Pubitemid 34185305)
15. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. [Review]. Nature 2003;423:337-342.
16. Lacey DL, Timms E, Tan HL et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176. (Pubitemid 28180851)
17. Lewiecki EM: Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt) 2009;18:1615-1626.
18. Miller PD: Denosumab: anti-RANKL antibody. Curr Osteoporos Rep 2009;7:18-22.
19. Cummings SR, San Martin J, McClung MR, et al.: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-765.
20. Fouque-Aubert A, Chapurlat R: Influence of RANKL inhibition on immune system in the treatment of bone diseases. Joint Bone Spine 2008;75:5-10.
21. Anderson DM, Maraskovsky E, Billingsley WL, et al.: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-179. (Pubitemid 27507987)
22. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. [Review]. Cell 2001;104:487-501. (Pubitemid 32201945)
23. Bodmer JL, Schneider P, Tschopp J: The molecular architecture of the TNF superfamily. [Review]. Trends Biochem Sci 2002;27:19-26. (Pubitemid 34131621)
24. Hsu H, Lacey DL, Dunstan CR et al.: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-3545. (Pubitemid 29168945)
25. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB: Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem 1998;273:20551-20555. (Pubitemid 28377625)
26. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi YW: The TRAF family of signal transducers mediates NF-KAPPA-B activation by the TRANCE receptor. J Biol Chem 1998;273:28355-28359. (Pubitemid 28496137)
27. Kim HH, Lee DE, Shin JN, et al.: Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 1999;443:297-302. (Pubitemid 29080814)
28. Darnay BG, Ni J, Moore PA, Aggarwal BB: Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NFkappaB- inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 1999;274:7724-7731.
29. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC: The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem 1998;273:34120-34127.
30. Liu W, Xu D, Yang H, et al.: Functional identification of three RANK cytoplasmic motifs mediating osteoclast differentiation and function. J Biol Chem 2004;279:54759-54769. (Pubitemid 40053221)
31. Chen T, Feng X: Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors. Assay Drug Dev Technol 2006;4:473-482. (Pubitemid 44793594)
32. McHugh KP, Hodivala-Dilke K, Zheng MH, et al.: Mice lacking b3 integrins are osteosclerotic due to dysfunctional osteoclasts. J Clin Invest 2000;105: 433-440. (Pubitemid 30127243)
33. Takeshita S, Kaji K, Kudo A: Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 2000;15:1477-1488. (Pubitemid 30484517)
34. Xu D, Shi Z, McDonald J, et al.: Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members. Biochem J 2004;383:219-225. (Pubitemid 39446682)
35. Ory DS, Neugeboren BA, Mulligan RC: A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 1996;93:11400-11406. (Pubitemid 26347133)
36. Shui C, Riggs BL, Khosla S: The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand. Calcif Tissue Int 2002;71:437-446. (Pubitemid 36929607)
37. Battaglino R, Kim D, Fu B, Fu XY, Stashenko P: c-Myc is required for osteoclast differentiation. J Bone Miner Res 2002;17:763-773. (Pubitemid 34441892)
38. Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS: NF-kappa B-mediated chemoresistance in breast cancer cells. Surgery 2001;130:143-150. (Pubitemid 32721661)
39. Shin HM, Kim MH, Kim BH, et al.: Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett 2004;571:50-54. (Pubitemid 38992922)
40. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;10:67-73. (Pubitemid 29278954)
41. Wong BR, Josien R, Lee SY, et al.: TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-2080. (Pubitemid 28013694)
42. Kong YY, Yoshida H, Sarosi I, et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397: 315-323.